The IPO-linked pharmaceutical and diagnostics company PharmEasy has been in the headlines since May after the company acquired Medlife and ThyroCare. It has also mopped up consecutive rounds this year, raising just Rs 1637.8 crore, or $ 217 million, in what appears to be a pre-IPO round for the Mumbai-based company.
In the past month, PharmEasy made two assignments. In the first tranche, 2,24,740 shares were allotted at an issue price of Rs.5,865 per share to raise Rs.131.81 billion, according to regulatory filings. The company has also approved the allotment of 17,58,024 shares and 7,94,345 preferred shares at an issue price of Rs.5,900 per share to raise Rs.1506 billion.
In total, the company has raised $ 217 million since the middle of last month. Corresponding TrickypediaPharmEasy ‘s estimates have raised new funds valued at $ 5.5 billion to $ 5.7 billion. The Tiger Global-backed company was valued at $ 4.2 billion during its final tranche in June.
In the current round, SARV Investments Limited has invested Rs 444 billion, followed by Amansa, Orbimed and Steadview Capital which have invested Rs 370 billion, Rs 222 billion and Rs 111 billion, respectively.
The remainder was invested by Janus Henderson Fund, Neuberger Berman, Amaara Partners, RISA Partners and individuals such as Mayank Kapoor, Shaunak Joshi and Varun Vohra.
According to an ET report, the existing investors of PharmEasy have dumped shares worth around 130 to 140 million US dollars in a secondary share sale and the total round was closed for around 350 million US dollars. The total financing of PharmEasy since April of this year, including ancillary components, thus amounts to 1 billion US dollars. The company had increased $ 300 million in June.
Following the reallocation of shares, Prosus (Naspers) is the largest shareholder in PharmEasy, which holds 11.43% of the shares in the company. Temasek is the second largest shareholder with 10.29%, followed by TPG Growth, Prasid Uno Family Trust and Evermed Holdings with 6.31%, 6.07% and 5.83% of the shares, respectively.
The full participation (with the exception of the co-founders) can be seen below.
PharmEasy, which reportedly launched an IPO valued at $ 9-10 billion Control participation A Healthcare Supply Chain Startup Aknamed in a Primary and Secondary Deal.
Corresponding TrickypediaIt is estimated that PharmEasy acquired the Bengaluru-based company for around $ 144 million. Aknamed was the third acquisition for PharmEasy in 2021. It had it in June acquired 66.1% of the shares in the listed diagnostics company Thyrocare for about Rs 4,546 crore and Medlife in May.